Malaria Drug Doesn't Boost Survival Odds With Prion Diseases

WEDNESDAY, March 11 (HealthDay News) -- The drug quinacrine doesn't prolong survival of patients with brain-wasting prion diseases such as Creutzfeldt-Jakob disease (CJD), British researchers say.

Currently, there is no way to prevent or reverse the progression of prion diseases. However, quinacrine -- an oral drug used to treat malaria and some forms of arthritis -- has been shown to be effective in treating prion-infected mouse cells.

This study included 107 patients, aged 12 and older, with prion disease. They underwent neurological assessments and clinical exams at the start of the study and again one, two, four and six months later. After that, the patients were examined every three months.

Some patients started taking 300 milligrams of quinacrine per day at the start of the study, one group started taking the drug later in the study, and others didn't take quinacrine.

During the study, 78 patients died, including 26 who took the drug immediately and 52 who initially took no quinacrine or delayed treatment.

After adjusting for factors such as disease severity and type of prion disease, the researchers found no significant difference in survival rates between those who took quinacrine and those who initially didn't take the drug.

The study was released online and was expected to be published in the April print issue of The Lancet Neurology.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about prion diseases.

SOURCE: The Lancet Neurology, news release, March 10, 2009

Join the Discussion
blog comments powered by Disqus
 
You Might Also Like...
See It, Share It
PHOTO: A visitor holds an Xbox One controller during the EGX gaming conference at Earls Court in London, Sept. 25, 2014.
Chris Ratcliffe/Bloomberg/Getty Images
Minecraft Creator Buys Ridiculous $70 Million Mansion
MLS | Inset: Yui Mok/Press Association/AP Photo
PHOTO: James Franco, left, and Seth Rogen in a scene from the The Interview.
Ed Araquel/Columbia Pictures/Sony/AP Photo